Memory Functioning and Antidepressant Treatment
Major Depressive Disorder
Drug: Bupropion XL
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Memory Functioning and Antidepressant Treatment: A Randomized Controlled Trial Comparing Escitalopram and Bupropion XL|
- General Verbal Memory-California Verbal Learning Test® -2nd ed (CVLT® -II)
- Hamilton Rating Scale for Depression - 17-Item
- Clinical Global Impression Severity and Improvement Ratings
- Short Term & Working Memory: Wechsler Memory Scales III
- Nonverbal Memory - Faces
- WMS III Logical Memory (Prose Recall)
- Nonverbal Memory - Spatial Memory
- Shipley Institute of Living Scale
- Prospective Memory
|Study Start Date:||December 2005|
Purpose of the Present Study:
The purpose of the present study is to comprehensively evaluate memory functioning of MDD patients before and after 8 weeks of antidepressant treatment with bupropion-XL or escitalopram. A neuropsychological test battery will incorporate multiple aspects of memory functioning including: short-term & working memory; verbal, non-verbal, spatial and prospective memory.
Major Research Questions:
- Which subtypes of memory at baseline are more impaired?
- What is the relationship between memory impairment and symptom severity and previous number of episodes or duration of illness?
- Is successful AD treatment associated with improvement in memory functioning?
- Is there a main effect by AD type?
- On which subtypes of memory do patients improve, worsen, or remain neutral in the 2 different AD groups? (Main effect of memory type?)
- What is the relationship between change in memory function and symptomatic outcome?
This is a randomized, double-blind, double-dummy trial comparing the memory functioning of depressed subjects before and after 8 weeks of treatment with bupropion-XL as compared to escitalopram.
All consenting, eligible subjects will receive either active bupropion-XL or active escitalopram following the baseline visit. Doses will be fixed with an opportunity for dose reduction if subjects are unable to tolerate fixed dose.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00296933
|University Health Network|
|Toronto, Ontario, Canada, M5G 2C4|
|Principal Investigator:||Sidney H Kennedy, MD||University Health Network, Toronto|